Advertisement
Screener

LEXICON PHARMACEUTICALS, INC. (LXRX) Interest Expense

2.8 / 5 stars · 68/120 Roast Me

LEXICON PHARMACEUTICALS, INC. Interest Expense

LEXICON PHARMACEUTICALS, INC. (LXRX) reported Interest Expense of $3.90 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-08.

Discontinued › Expense Statement › Interest Expense

us-gaap:InterestExpense · last filed 2023-11-08

  • LEXICON PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-09-30 was $3.90M, a 351.27% increase year-over-year.
  • LEXICON PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-06-30 was $1.96M, a 178.81% increase year-over-year.
  • LEXICON PHARMACEUTICALS, INC. interest expense for the quarter ending 2023-03-31 was $1.82M, a 1555.45% increase year-over-year.
  • LEXICON PHARMACEUTICALS, INC. interest expense for the quarter ending 2022-12-31 was $1.10M, a 273.90% increase year-over-year.
  • LEXICON PHARMACEUTICALS, INC. interest expense for fiscal 2022 was $2.78M, a 246.63% increase from fiscal 2021.
  • LEXICON PHARMACEUTICALS, INC. interest expense for fiscal 2021 was $802.00K, a 94.49% decline from fiscal 2020.
  • LEXICON PHARMACEUTICALS, INC. interest expense for fiscal 2020 was $14.54M, a 29.66% decline from fiscal 2019.
  • LEXICON PHARMACEUTICALS, INC. interest expense for fiscal 2019 was $20.68M, a 0.49% decline from fiscal 2018.
Period endInterest Expense 3 monthInterest Expense 3 month as first filedInterest Expense 6 monthInterest Expense 6 month as first filedInterest Expense 9 monthInterest Expense 9 month as first filedInterest Expense 12 month
2023-09-30$3.90M
10-Q · filed 2023-11-08
$5.86M
derived: sum of 2 quarters · filed 2023-11-08
$7.68M
10-Q · filed 2023-11-08
$8.78M
derived: sum of 4 quarters · filed 2023-11-08
2023-06-30$1.96M
10-Q · filed 2023-08-04
$3.78M
10-Q · filed 2023-08-04
$4.88M
derived: sum of 3 quarters · filed 2023-08-04
$5.75M
derived: sum of 4 quarters · filed 2023-11-08
2023-03-31$1.82M
10-Q · filed 2023-05-04
$2.92M
derived: sum of 2 quarters · filed 2023-05-04
$3.79M
derived: sum of 3 quarters · filed 2023-11-08
$4.49M
derived: sum of 4 quarters · filed 2023-11-08
2022-12-31$1.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03
$1.97M
derived: sum of 2 quarters · filed 2023-11-08
$2.67M
derived: sum of 3 quarters · filed 2023-11-08
$2.78M
10-K · filed 2023-03-03
2022-09-30$864.00K
10-Q · filed 2023-11-08
$1.57M
derived: sum of 2 quarters · filed 2023-11-08
$1.68M
10-Q · filed 2023-11-08
$1.97M
derived: sum of 4 quarters · filed 2023-11-08
2022-06-30$703.00K
10-Q · filed 2023-08-04
$813.00K
10-Q · filed 2023-08-04
$1.11M
derived: sum of 3 quarters · filed 2023-08-04
$1.28M
derived: sum of 4 quarters · filed 2023-08-04
2022-03-31$110.00K
10-Q · filed 2023-05-04
$405.00K
derived: sum of 2 quarters · filed 2023-05-04
$576.00K
derived: sum of 3 quarters · filed 2023-05-04
$745.00K
derived: sum of 4 quarters · filed 2023-05-04
2021-12-31$295.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03
$466.00K
derived: sum of 2 quarters · filed 2023-03-03
$635.00K
derived: sum of 3 quarters · filed 2023-03-03
$802.00K
10-K · filed 2023-03-03
2021-09-30$171.00K
10-Q · filed 2022-11-09
$340.00K
derived: sum of 2 quarters · filed 2022-11-09
$507.00K
10-Q · filed 2022-11-09
$677.00K
derived: sum of 4 quarters · filed 2023-03-03
2021-06-30$169.00K
10-Q · filed 2022-08-03
$336.00K
10-Q · filed 2022-08-03
$506.00K
derived: sum of 3 quarters · filed 2023-03-03
$4.62M
derived: sum of 4 quarters · filed 2023-03-03
2021-03-31$167.00K
10-Q · filed 2022-05-05
$337.00K
derived: sum of 2 quarters · filed 2023-03-03
$4.46M
derived: sum of 3 quarters · filed 2023-03-03
$9.58M
derived: sum of 4 quarters · filed 2023-03-03
2020-12-31$170.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-03
$4.29M
derived: sum of 2 quarters · filed 2023-03-03
$9.41M
derived: sum of 3 quarters · filed 2023-03-03
$14.54M
10-K · filed 2023-03-03
2020-09-30$4.12M
10-Q · filed 2021-11-09
$9.24M
derived: sum of 2 quarters · filed 2021-11-09
$14.37M
10-Q · filed 2021-11-09
$19.57M
derived: sum of 4 quarters · filed 2022-03-10
2020-06-30$5.13M
10-Q · filed 2021-08-06
$10.26M
10-Q · filed 2021-08-06
$15.45M
derived: sum of 3 quarters · filed 2022-03-10
$20.65M
derived: sum of 4 quarters · filed 2022-03-10
2020-03-31$5.13M
10-Q · filed 2021-05-06
$10.32M
derived: sum of 2 quarters · filed 2022-03-10
$15.53M
derived: sum of 3 quarters · filed 2022-03-10
$20.69M
derived: sum of 4 quarters · filed 2022-03-10
2019-12-31$5.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
$10.39M
derived: sum of 2 quarters · filed 2022-03-10
$15.56M
derived: sum of 3 quarters · filed 2022-03-10
$20.68M
10-K · filed 2022-03-10
2019-09-30$5.20M
10-Q · filed 2020-10-30
$10.37M
derived: sum of 2 quarters · filed 2020-10-30
$15.48M
10-Q · filed 2020-10-30
$20.71M
derived: sum of 4 quarters · filed 2021-03-12
2019-06-30$5.16M
10-Q · filed 2020-07-29
$10.28M
10-Q · filed 2020-07-29
$15.51M
derived: sum of 3 quarters · filed 2021-03-12
$20.76M
derived: sum of 4 quarters · filed 2021-03-12
2019-03-31$5.12M
10-Q · filed 2020-04-27
$10.34M
derived: sum of 2 quarters · filed 2021-03-12
$15.59M
derived: sum of 3 quarters · filed 2021-03-12
$20.78M
derived: sum of 4 quarters · filed 2021-03-12
2018-12-31$5.22M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
$10.48M
derived: sum of 2 quarters · filed 2021-03-12
$15.66M
derived: sum of 3 quarters · filed 2021-03-12
$20.78M
10-K · filed 2021-03-12
2018-09-30$5.25M
10-Q · filed 2019-11-07
$10.44M
derived: sum of 2 quarters · filed 2019-11-07
$15.55M
10-Q · filed 2019-11-07
$15.55M
10-Q · filed 2018-11-01
$17.71M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30$5.19M
10-Q · filed 2019-08-01
$10.30M
10-Q · filed 2019-08-01
$10.30M
10-Q · filed 2018-07-30
$12.46M
derived: sum of 3 quarters · filed 2020-03-12
$14.08M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31$5.11M
10-Q · filed 2019-05-01
$5.11M
10-Q · filed 2018-05-03
$7.28M
derived: sum of 2 quarters · filed 2020-03-12
$8.89M
derived: sum of 3 quarters · filed 2020-03-12
$10.51M
derived: sum of 4 quarters · filed 2020-03-12
2017-12-31$2.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$3.78M
derived: sum of 2 quarters · filed 2020-03-12
$5.40M
derived: sum of 3 quarters · filed 2020-03-12
$6.98M
10-K · filed 2020-03-12
2017-09-30$1.62M
10-Q · filed 2018-11-01
$3.23M
derived: sum of 2 quarters · filed 2018-11-01
$4.82M
10-Q · filed 2018-11-01
$6.46M
derived: sum of 4 quarters · filed 2019-03-15
2017-06-30$1.61M
10-Q · filed 2018-07-30
$3.20M
10-Q · filed 2018-07-30
$4.84M
derived: sum of 3 quarters · filed 2019-03-15
$6.48M
derived: sum of 4 quarters · filed 2019-03-15
2017-03-31$1.59M
10-Q · filed 2018-05-03
$3.22M
derived: sum of 2 quarters · filed 2019-03-15
$4.87M
derived: sum of 3 quarters · filed 2019-03-15
$6.51M
derived: sum of 4 quarters · filed 2019-03-15
2016-12-31$1.63M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15
$3.28M
derived: sum of 2 quarters · filed 2019-03-15
$4.92M
derived: sum of 3 quarters · filed 2019-03-15
$6.57M
10-K · filed 2019-03-15
2016-09-30$1.65M
10-Q · filed 2017-11-08
$3.28M
derived: sum of 2 quarters · filed 2017-11-08
$4.93M
10-Q · filed 2017-11-08
$6.61M
derived: sum of 4 quarters · filed 2018-03-01
2016-06-30$1.64M
10-Q · filed 2017-08-01
$3.29M
10-Q · filed 2017-08-01
$4.96M
derived: sum of 3 quarters · filed 2018-03-01
$6.65M
derived: sum of 4 quarters · filed 2018-03-01
2016-03-31$1.65M
10-Q · filed 2017-05-04
$3.33M
derived: sum of 2 quarters · filed 2018-03-01
$5.01M
derived: sum of 3 quarters · filed 2018-03-01
$6.67M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31$1.68M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01
$3.37M
derived: sum of 2 quarters · filed 2018-03-01
$5.02M
derived: sum of 3 quarters · filed 2018-03-01
$6.72M
10-K · filed 2018-03-01
2015-09-30$1.69M
10-Q · filed 2016-11-07
$3.34M
derived: sum of 2 quarters · filed 2016-11-07
$5.04M
10-Q · filed 2016-11-07
$5.94M
derived: sum of 4 quarters · filed 2017-03-06
2015-06-30$1.66M
10-Q · filed 2016-08-04
$3.36M
10-Q · filed 2016-08-04
$4.25M
derived: sum of 3 quarters · filed 2017-03-06
$4.70M
derived: sum of 4 quarters · filed 2017-03-06
2015-03-31$1.70M
10-Q · filed 2016-05-05
$2.59M
derived: sum of 2 quarters · filed 2017-03-06
$3.04M
derived: sum of 3 quarters · filed 2017-03-06
$3.50M
derived: sum of 4 quarters · filed 2017-03-06
2014-12-31$892.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-06
$1.34M
derived: sum of 2 quarters · filed 2017-03-06
$1.80M
derived: sum of 3 quarters · filed 2017-03-06
$2.25M
10-K · filed 2017-03-06
2014-09-30$449.00K
10-Q · filed 2015-11-09
$904.00K
derived: sum of 2 quarters · filed 2015-11-09
$1.36M
10-Q · filed 2015-11-09
$1.84M
derived: sum of 4 quarters · filed 2016-03-11
2014-06-30$455.00K
10-Q · filed 2015-08-07
$912.00K
10-Q · filed 2015-08-07
$1.39M
derived: sum of 3 quarters · filed 2016-03-11
$1.88M
derived: sum of 4 quarters · filed 2016-03-11
2014-03-31$457.00K
10-Q · filed 2015-05-05
$934.00K
derived: sum of 2 quarters · filed 2016-03-11
$1.43M
derived: sum of 3 quarters · filed 2016-03-11
$1.92M
derived: sum of 4 quarters · filed 2016-03-11
2013-12-31$477.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-11
$969.00K
derived: sum of 2 quarters · filed 2016-03-11
$1.47M
derived: sum of 3 quarters · filed 2016-03-11
$1.97M
10-K · filed 2016-03-11
2013-09-30$492.00K
10-Q · filed 2014-11-06
$988.00K
derived: sum of 2 quarters · filed 2014-11-06
$1.49M
10-Q · filed 2014-11-06
$2.01M
derived: sum of 4 quarters · filed 2015-03-12
2013-06-30$496.00K
10-Q · filed 2014-08-07
$1.00M
10-Q · filed 2014-08-07
$1.52M
derived: sum of 3 quarters · filed 2015-03-12
$2.05M
derived: sum of 4 quarters · filed 2015-03-12
2013-03-31$506.00K
10-Q · filed 2014-05-08
$1.03M
derived: sum of 2 quarters · filed 2015-03-12
$1.55M
derived: sum of 3 quarters · filed 2015-03-12
$2.08M
derived: sum of 4 quarters · filed 2015-03-12
2012-12-31$520.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-12
$1.05M
derived: sum of 2 quarters · filed 2015-03-12
$1.58M
derived: sum of 3 quarters · filed 2015-03-12
$2.11M
10-K · filed 2015-03-12
2012-09-30$527.00K
10-Q · filed 2013-11-12
$1.06M
derived: sum of 2 quarters · filed 2013-11-12
$1.59M
10-Q · filed 2013-11-12
$2.15M
derived: sum of 4 quarters · filed 2014-03-07
2012-06-30$530.00K
10-Q · filed 2013-08-01
$1.07M
10-Q · filed 2013-08-01
$1.62M
derived: sum of 3 quarters · filed 2014-03-07
$2.18M
derived: sum of 4 quarters · filed 2014-03-07
2012-03-31$537.00K
10-Q · filed 2013-05-10
$1.09M
derived: sum of 2 quarters · filed 2014-03-07
$1.65M
derived: sum of 3 quarters · filed 2014-03-07
$2.46M
derived: sum of 4 quarters · filed 2014-03-07
2011-12-31$551.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-07
$1.11M
derived: sum of 2 quarters · filed 2014-03-07
$1.92M
derived: sum of 3 quarters · filed 2014-03-07
$2.53M
10-K · filed 2014-03-07
2011-09-30$560.00K
10-Q · filed 2012-11-07
$1.37M
derived: sum of 2 quarters · filed 2012-11-07
$1.98M
10-Q · filed 2012-11-07
$2.60M
derived: sum of 4 quarters · filed 2013-03-11
2011-06-30$810.00K
10-Q · filed 2012-08-02
$1.42M
10-Q · filed 2012-08-02
$2.04M
derived: sum of 3 quarters · filed 2013-03-11
$2.68M
derived: sum of 4 quarters · filed 2013-03-11
2011-03-31$607.00K
10-Q · filed 2012-05-03
$1.23M
derived: sum of 2 quarters · filed 2013-03-11
$1.87M
derived: sum of 3 quarters · filed 2013-03-11
$2.60M
derived: sum of 4 quarters · filed 2013-03-11
2010-12-31$626.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-11
$1.26M
derived: sum of 2 quarters · filed 2013-03-11
$1.99M
derived: sum of 3 quarters · filed 2013-03-11
$2.72M
10-K · filed 2013-03-11
2010-09-30$637.00K
10-Q · filed 2011-11-01
$1.37M
derived: sum of 2 quarters · filed 2011-11-01
$2.09M
10-Q · filed 2011-11-01
2010-06-30$729.00K
10-Q · filed 2011-08-09
$1.46M
10-Q · filed 2011-08-09
2009-12-31$2.97M
10-K · filed 2012-03-08

Similar stocks

Stock NameCountryMarket CapPE Ratio
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
GERON CORP (GERN)United States$0.803B-12.14
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
ARDELYX, INC. (ARDX)United States$0.857B-22.86
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78